HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O'Regan, D. J. Articles by Westaby, S. Search for Related Content PubMed PubMed Citation Articles by O'Regan, D. J. Articles by Westaby, S.

The Annals of Thoracic Surgery, Vol 58, 778-781, Copyright © 1994 by The Society of Thoracic Surgeons

ARTICLES

Topical aprotinin in cardiac operations

DJ O'Regan, N Giannopoulos, N Mediratta, SW Kendall, A Forni, R Pillai and S Westaby
Oxford Heart Centre, John Radcliffe Hospital, England.

We performed a prospective, randomized, double-blind trial of topical aprotinin versus placebo in 100 patients undergoing cardiac operations with cardiopulmonary bypass. Fifty-five patients received aprotinin. Forty underwent coronary artery bypass grafting (CABG) and 15 valve replacement +/- CABG. Of 45 patients in the control group 38 underwent CABG and 7 valve replacement +/- CABG. Aprotinin (50 mL; 70 mg) or placebo was applied topically to the heart, pericardium, and mediastinum before sternal closure. There were five reentries for bleeding with a surgical site identified in four. Mean blood loss was significantly less in the aprotinin group (653 versus 903 mL; p = 0.002), and fewer aprotinin patients received blood as a volume expander (67.5% versus 88%; p = 0.03). In coronary patients alone when aspirin administration was continued until the day of operation there was no difference between treatment and placebo groups (768 versus 879 mL). When aspirin administration was discontinued 2 weeks before operation there was a significant difference (558 versus 884 mL; p = 0.016) as in the group overall. This provides the potential for intrapericardial instillation for patients with excessive postoperative bleeding.

This article has been cited by other articles:

				L. Y. Lee, W. J. DeBois, K. H. Krieger, and O. W. Isom Transfusion Therapy and Blood Conservation Card. Surg. Adult, January 1, 2008; 3(2008): 415 - 430. [Full Text]

				D. Baric, B. Biocina, D. Unic, Z. Sutlic, I. Rudez, V. B. Vrca, K. Brkic, and M. Ivkovic Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 366 - 371. [Abstract] [Full Text] [PDF]

				M. Sirlak, S. Eryilmaz, L. Yazicioglu, U. Kiziltepe, Z. Eyileten, M. S. Durdu, R. Tasoz, N. T. Eren, A. Aral, B. Kaya, et al. Comparative study of microfibrillar collagen hemostat (Colgel) and oxidized cellulose (Surgicel) in high transfusion-risk cardiac surgery J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 666 - 670. [Abstract] [Full Text] [PDF]

				J. M. Karski and J. T. Balatbat Blood Conservation Strategies in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2003; 7(2): 175 - 188. [Abstract] [PDF]

				L. Y. Lee, W. J. DeBois, K. H. Krieger, and O. W. Isom Transfusion Therapy and Blood Conservation Card. Surg. Adult, January 1, 2003; 2(2003): 389 - 400. [Full Text]

				F. Isgro, O. Stanisch, A.-H Kiessling, S. Gurler, P. Hellstern, and W. Saggau Topical application of aprotinin in cardiac surgery Perfusion, September 1, 2002; 17(5): 347 - 351. [Abstract] [PDF]

				S. Westaby, S. Saito, and T. Katsumata Acute type A dissection: conservative methods provide consistently low mortality Ann. Thorac. Surg., March 1, 2002; 73(3): 707 - 713. [Abstract] [Full Text] [PDF]

				K. N. Maquelin, R. Nieuwland, E. G. W. M. Lentjes, A. N. Boing, B. Mochtar, L. Eijsman, and A. Sturk Aprotinin administration in the pericardial cavity does not prevent platelet activation J. Thorac. Cardiovasc. Surg., September 1, 2000; 120(3): 552 - 557. [Abstract] [Full Text] [PDF]

				G. J. Despotis and L. T. Goodnough Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery Ann. Thorac. Surg., August 1, 2000; 70(2): S20 - 32. [Abstract] [Full Text] [PDF]

				M. De Bonis, F. Cavaliere, F. Alessandrini, E. Lapenna, F. Santarelli, U. Moscato, R. Schiavello, and G. F. Possati TOPICAL USE OF TRANEXAMIC ACID IN CORONARY ARTERY BYPASS OPERATIONS: A DOUBLE-BLIND, PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED STUDY J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 575 - 580. [Abstract] [Full Text] [PDF]

				F. Bizzarri, E. Carone, G. Capannini, G. Davoli, G. Lisi, M. Maccherini, G. Sani, and M. Toscano Bleeding reduction in cardiac surgery: A combined approach J. Thorac. Cardiovasc. Surg., May 1, 1998; 115(5): 1227 - 1227. [Full Text] [PDF]

				S. Westaby Aprotinin Fifteen Years Later Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 366 - 375. [Abstract] [PDF]

				N. Hayashida, T. Isomura, T. Sato, H. Maruyama, K. Kosuga, and S. Aoyagi EFFECTS OF MINIMAL-DOSE APROTININ ON CORONARY ARTERY BYPASS GRAFTING J. Thorac. Cardiovasc. Surg., August 1, 1997; 114(2): 261 - 269. [Abstract] [Full Text]

				S. Cicek and D. A. Theodoro Topical Aprotinin in Cardiac Operations: A Note of Caution Ann. Thorac. Surg., March 1, 1996; 61(3): 1039 - 1040. [Full Text]

				S. Cicek Topical Aprotinin in Cardiac Operations Ann. Thorac. Surg., October 1, 1995; 60(4): 1155 - 1155. [Full Text]

				S. Cicek, H. Tatar, U. Demirklc, and E. Kuralay Topical use of aprotinin in cardiac surgery J. Thorac. Cardiovasc. Surg., August 1, 1995; 110(2): 568 - 569. [Full Text]